再鼎医药

ZLAB NASDAQ
32.37
+0.43
+1.35%
盘后: 32.37 0 0.00% 16:34 06/18 EDT
开盘
31.90
昨收
31.94
最高
32.45
最低
31.60
成交量
16.93万
成交均量(3M)
21.22万
52周最高
33.86
52周最低
14.29
换手率
0.26%
市值
18.89亿
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供再鼎医药 ZLAB股票价格,再鼎医药股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Zai Lab Ltd is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include three drug candidates with greater China rights and three drug candidates with global rights. The greater China rights drug candidates include Niraparib (ZL-2306), Omadacycline (ZL-2401) and ZL-2301. The global rights drug candidates include Fugan (ZL-3101), ZL-2302 and ZL-1101.
展开 >

最近浏览

名称
价格
涨跌幅